Advertisement

Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLAR

Published:March 15, 2022DOI:https://doi.org/10.1016/j.jid.2022.02.013
      Psoriasis is a chronic inflammatory disease affecting 3% of the US population (
      • Armstrong A.W.
      • Mehta M.D.
      • Schupp C.W.
      • Gondo G.C.
      • Bell S.J.
      • Griffiths C.E.M.
      Psoriasis prevalence in adults in the United States.
      ). The negative effect of psoriasis on health-related QOL is similar to that of other serious chronic diseases (
      • Rapp S.R.
      • Feldman S.R.
      • Exum M.L.
      • Fleischer Jr., A.B.
      • Reboussin D.M.
      Psoriasis causes as much disability as other major medical diseases.
      ). Data on the QOL burden of psoriasis among non-White populations are limited. This study evaluated racial/ethnic differences in the effect of psoriasis on health-related QOL, as measured by the Dermatology Life Quality Index (DLQI), among North American patients with psoriasis enrolled in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

      Abbreviation:

      DLQI (Dermatology Life Quality Index)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'
      Society Members (SID/ESDR), remember to log in for access.

      Subscribe:

      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Armstrong A.W.
        • Mehta M.D.
        • Schupp C.W.
        • Gondo G.C.
        • Bell S.J.
        • Griffiths C.E.M.
        Psoriasis prevalence in adults in the United States.
        JAMA Dermatol. 2021; 157: 940-946
        • Barbieri J.S.
        • Shin D.B.
        • Syed M.N.
        • Takeshita J.
        • Gelfand J.M.
        Evaluation of the frequency of "not relevant" responses on the Dermatology Life Quality Index by sociodemographic characteristics of patients with psoriasis.
        JAMA Dermatol. 2020; 156: 446-450
        • Finlay A.Y.
        • Khan G.K.
        Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.
        Clin Exp Dermatol. 1994; 19: 210-216
        • Fischer A.H.
        • Shin D.B.
        • Gelfand J.M.
        • Takeshita J.
        Health care utilization for psoriasis in the United States differs by race: an analysis of the 2001–2013 Medical Expenditure Panel Surveys.
        J Am Acad Dermatol. 2018; 78: 200-203
        • Hongbo Y.
        • Thomas C.L.
        • Harrison M.A.
        • Salek M.S.
        • Finlay A.Y.
        Translating the science of quality of life into practice: what do dermatology life quality index scores mean?.
        J Invest Dermatol. 2005; 125: 659-664
        • Kimball A.B.
        • Leonardi C.
        • Stahle M.
        • Gulliver W.
        • Chevrier M.
        • Fakharzadeh S.
        • et al.
        Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).
        Br J Dermatol. 2014; 171: 137-147
        • Mazzotti E.
        • Barbaranelli C.
        • Picardi A.
        • Abeni D.
        • Pasquini P.
        Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis.
        Acta Derm Venereol. 2005; 85: 409-413
        • Mazzotti E.
        • Picardi A.
        • Sampogna F.
        • Sera F.
        • Pasquini P.
        • Abeni D.
        • et al.
        Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis.
        Br J Dermatol. 2003; 149: 318-322
        • Papp K.A.
        • Strober B.
        • Augustin M.
        • Calabro S.
        • Londhe A.
        • Chevrier M.
        • on behalf of the PSOLAR investigators and Steering Committee
        PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
        J Drugs Dermatol. 2012; 11: 1210-1217
        • Rapp S.R.
        • Feldman S.R.
        • Exum M.L.
        • Fleischer Jr., A.B.
        • Reboussin D.M.
        Psoriasis causes as much disability as other major medical diseases.
        J Am Acad Dermatol. 1999; 41: 401-407
        • Rencz F.
        • Gulácsi L.
        • Péntek M.
        • Poór A.K.
        • Sárdy M.
        • Holló P.
        • et al.
        Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.
        Br J Dermatol. 2018; 179: 1102-1108
        • Rencz F.
        • Gulácsi L.
        • Péntek M.
        • Szegedi A.
        • Remenyik É.
        • Bata-Csörgő Z.
        • et al.
        DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea.
        Br J Dermatol. 2020; 182: 1167-1175
        • Shah S.K.
        • Arthur A.
        • Yang Y.C.
        • Stevens S.
        • Alexis A.F.
        A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept.
        J Drugs Dermatol. 2011; 10: 866-872
        • Takeshita J.
        • Gelfand J.M.
        • Li P.
        • Pinto L.
        • Yu X.
        • Rao P.
        • et al.
        Psoriasis in the US medicare population: prevalence, treatment, and factors associated with biologic use.
        J Invest Dermatol. 2015; 135: 2955-2963
        • van Winden M.E.C.
        • Ter Haar E.L.M.
        • Groenewoud J.M.M.
        • van de Kerkhof P.C.M.
        • de Jong E.M.G.J.
        • Lubeek S.F.K.
        Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups.
        Br J Dermatol. 2021; 184: 759-762